We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




POC System Delivers Lab-Quality PCR Results Directly from Swab Sample in Minutes

By LabMedica International staff writers
Posted on 09 Jun 2025

Medical and laboratory staff in primary care settings are multi-skilled and routinely multitask to deliver care with the speed and convenience expected of modern medicine. More...

This places a strong requirement for ease-of-use on the tools they utilize. To address this requirement, a new ultra-fast point-of-care molecular diagnostics platform delivers highly sensitive PCR results for key respiratory pathogens directly from a swab sample in less than ten minutes.

The VELO system from LEX Diagnostics (Cambridgeshire, UK) uses a proprietary cartridge-based design that eliminates the need for external liquid handling, providing ease of use and reliability. The system supports multiplex testing for key respiratory pathogens, including Influenza A, Influenza B, and COVID-19, and delivers PCR results in six to ten minutes. The VELO system can be easily integrated into clinical workflows across primary care settings, urgent care clinics, pharmacies, physician office laboratories, and decentralized acute settings.

LEX has completed clinical studies of the VELO system and the Influenza/Covid assay in the U.S. during the 2024/2025 respiratory season. The company has submitted dual applications to the U.S. Food and Drug Administration (FDA) for 510(k) clearance and CLIA waived status for its VELO system. It expects U.S. market clearance in late 2025 or early 2026, which is in line with the anticipated FDA review timelines.

“We believe the LEX VELO system will redefine point-of-care testing by equipping healthcare providers with lab-quality results in minutes, enabling faster clinical decisions and improved patient outcomes without compromising quality while improving workflow—an achievement that will set us apart in the marketplace,” said Ed Farrell, Chief Executive Officer of LEX Diagnostics.

Related Links:
LEX Diagnostics


New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.